Tirzepatide

What it is

Tirzepatide is a 39-amino-acid synthetic peptide developed by Eli Lilly that functions as a dual agonist at both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. It was the first agent in this novel “twincretin” class to receive FDA approval — Mounjaro for type 2 diabetes (May 2022) and Zepbound for chronic weight management (November 2023).

The molecule contains a C20 fatty diacid moiety attached via a linker, similar to semaglutide’s albumin-binding modification, providing a half-life of approximately 5 days and enabling once-weekly subcutaneous dosing. Tirzepatide’s amino acid sequence is based on native GIP rather than GLP-1, but it has been modified to bind both receptors with high affinity. Notably, it shows greater agonism at GIP receptors than at GLP-1 receptors at clinically relevant concentrations — a profile distinct from native GIP, which is a much weaker GLP-1 receptor agonist.

Mechanism of action

The dual GIP/GLP-1 mechanism creates effects that are more than additive in many parameters. GLP-1 receptor activation produces the same effects as semaglutide: glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, and central appetite reduction. GIP receptor activation contributes additional effects:

• Adipose tissue: GIP enhances insulin sensitivity in adipocytes and may improve lipid storage capacity, potentially reducing ectopic fat deposition (in liver and muscle) during weight gain.
• Bone: GIP receptors are expressed on osteoblasts; GIP signaling supports bone formation, raising hopes that tirzepatide may have neutral or favorable effects on bone health during weight loss.
• Insulin sensitivity: the GIP component appears to amplify insulin’s peripheral effects beyond what GLP-1 monotherapy achieves.
• Nausea modulation: some evidence suggests GIP receptor activation may attenuate the nausea otherwise produced by GLP-1 agonism, potentially improving tolerability.

Research findings

SURPASS program (type 2 diabetes): Five SURPASS trials enrolled approximately 6,200 patients comparing tirzepatide to placebo, semaglutide 1 mg, insulin degludec, and insulin glargine. SURPASS-2 (2021, NEJM) directly compared tirzepatide 5/10/15 mg to semaglutide 1 mg over 40 weeks. All tirzepatide doses produced superior HbA1c reduction (-2.01 to -2.30% vs. -1.86%) and superior weight loss (-7.6 to -11.2 kg vs. -5.7 kg). The 15 mg dose produced nearly twice the weight loss of semaglutide 1 mg.

SURMOUNT-1 (chronic weight management): Published 2022 in NEJM. 2,539 adults without diabetes randomized to tirzepatide 5/10/15 mg or placebo for 72 weeks. Mean weight loss was 15.0%, 19.5%, and 20.9% across the three doses, vs. 3.1% with placebo. The 15 mg dose produced the largest mean weight loss documented for any non-surgical intervention. Approximately 50% of patients on the 10 and 15 mg doses lost ≥20% of body weight.

SURMOUNT-2 (T2DM): Demonstrated 12.8–14.7% weight loss with tirzepatide 10/15 mg in patients with type 2 diabetes — substantially greater than typically achieved in this population, where weight loss is usually attenuated.

SURMOUNT-OSA (obstructive sleep apnea): Tirzepatide significantly reduced apnea-hypopnea index alongside weight loss, leading to FDA approval for OSA in patients with obesity (December 2024).

SURPASS-CVOT (ongoing): Cardiovascular outcomes trial expected to read out in late 2024 or 2025.

How we use it at The Tide

Tirzepatide is increasingly our first-line therapy for patients prioritizing maximal weight loss outcomes — particularly those with metabolic syndrome, prediabetes, BMI above 30, or who have not responded adequately to semaglutide. Same baseline workup as semaglutide: fasting glucose, HbA1c, CMP, lipid panel, TSH, history review.

Standard titration: 2.5 mg weekly for 4 weeks → 5 mg for 4 weeks → 7.5 mg for 4 weeks → 10 mg for 4 weeks → 12.5 or 15 mg maintenance. For type 2 diabetes the target dose is often 10 mg; for weight management 10–15 mg is typical. We pair every protocol with structured nutrition guidance emphasizing protein intake (≥1.2–1.6 g/kg target body weight) and resistance training to preserve lean mass during weight loss.

Monitoring: CMP and lipids at 90 and 180 days, weight and tolerability at monthly check-ins, screening for pancreatitis and gallbladder symptoms throughout. Some patients benefit from baseline DEXA for body composition tracking; we discuss this on a case-by-case basis.

What good response looks like: 8–12% weight loss by month 3, 15–20% by month 6, with continued slower loss through month 12. Patients reaching weight loss plateaus may benefit from dose escalation, brief drug holidays, or recomposition-focused training periods.

Side effects and contraindications

Side effect profile parallels semaglutide but is often more pronounced during titration: nausea, decreased appetite (which is the goal but can become uncomfortable), early satiety, occasional vomiting, fatigue, and constipation. Slow titration, adequate hydration, low-fat meals, and protein-forward eating mitigate most symptoms.

Same serious risks as semaglutide: pancreatitis, gallbladder events (somewhat higher rates than semaglutide in trials, perhaps reflecting more rapid weight loss), and theoretical medullary thyroid cancer concerns from rodent data. Diabetic retinopathy progression with rapid glycemic improvement is a consideration in patients with established eye disease.

Contraindicated in: pregnancy and breastfeeding, MEN-2, personal/family history of medullary thyroid cancer, history of pancreatitis, severe gastroparesis.

What we don’t yet know

Long-term cardiovascular outcomes data is pending (SURPASS-CVOT). Direct comparison of tirzepatide vs. semaglutide for cardiovascular benefit is unstudied. The optimal balance between aggressive titration (faster weight loss but more side effects) and slower titration is not well characterized. Effects on bone density during 20%+ weight loss remain an area of active study, though early signals from GIP-related mechanisms are encouraging. As with semaglutide, weight regain after discontinuation is the rule rather than the exception, but the long-term metabolic trajectory in patients who discontinue is still being mapped.